CoChat

PD‐1/PD‐L1 inhibitors in haematological malignancies: update 2017

Open access
Jelinek, Tomas, Mihalyova, Jana, Kascak, Michal, Duras, Juraj, Hajek, Roman · 2017 · Immunology
Cited by 122

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Summary: The introduction of PD‐1/PD‐L1 pathway inhibitors is an important landmark in solid oncology with unprecedented practice‐changing activity in various types of solid tumours. Among haematological malignancies, PD‐1/PD‐L1 inhibitors have been successful, so far, only in the treatment of classical Hodgkin lymphoma, which typically exhibits an over‐expression of PD‐1 ligands (PD‐L1, PD‐L2) due to alterations in chromosome 9p24.1. Such positive outcomes led to the US Food and Drug Administration approval of nivolumab use in relapsed Hodgkin lymphoma in 2016 as the first haematological indication. Although the results in other lymphoid malignancies have not been so striking, blockade of the PD‐1/PD‐L1 axis has led to meaningful responses in other lymphoma types such as diffuse large B‐cell lymphoma, follicular lymphoma or several T‐cell lymphomas. Monotherapy with PD‐1/PD‐L1 inhibitors in chronic lymphocytic leukaemia and multiple myeloma has been unsatisfactory, suggesting that a combinational approach with other synergistic drugs is needed. In the case of multiple myeloma, immunomodulatory agents together with corticosteroids represent the most promising combinations. Among myeloid malignancies, the anti‐PD‐1 monoclonal antibodies are examined dominantly in acute myeloid leukaemia and myelodysplastic syndromes in combination with potentially synergistic hypomethylating drugs such as 5‐azacitidine, resulting in promising outcomes that warrant further investigation. We have described all available clinical results of PD‐1/PD‐L1 inhibitors in haematological malignancies and discussed related toxicities, as well as highlighted crucial preclinical studies in this review.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/imm.12788

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 122

Metadata

Authors
Jelinek, T., Mihalyova, J., Kascak, M., Duras, J., & Hajek, R.
Venue
Immunology
Publisher
Wiley
Published
2017-08-04
Volume
152
Issue
3
Pages
357-371
ISSN
  • 0019-2805 (ISSN-L)
  • 1365-2567
OpenAlex
W2732403960
Cited by
122
References
17
FWCI
7.54
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PD‐1/PD‐L1 inhibitors in haematological malignancies: update 2017. https://app.cochat.ai/papers/10.1111/imm.12788
The paper
Jelinek, T., Mihalyova, J., Kascak, M., Duras, J., & Hajek, R. (2017). PD‐1/PD‐L1 inhibitors in haematological malignancies: update 2017. Immunology. https://doi.org/10.1111/imm.12788

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.